​

Amgen (AMGN) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Amgen Revenue Highlights

Latest Revenue (Y)

$36.75B

Latest Revenue (Q)

$9.56B

Main Segment (Y)

Other Products

Main Geography (Y)

UNITED STATES

Amgen Revenue by Period

Amgen Revenue by Year

DateRevenueChange
2025-12-31$36.75B9.95%
2024-12-31$33.42B18.57%
2023-12-31$28.19B7.09%
2022-12-31$26.32B1.32%
2021-12-31$25.98B2.18%
2020-12-31$25.42B8.83%
2019-12-31$23.36B-1.62%
2018-12-31$23.75B3.93%
2017-12-31$22.85B-0.62%
2016-12-31$22.99B6.14%
2015-12-31$21.66B7.97%
2014-12-31$20.06B7.43%
2013-12-31$18.68B8.17%
2012-12-31$17.27B10.80%
2011-12-31$15.58B3.51%
2010-12-31$15.05B2.81%
2009-12-31$14.64B-2.41%
2008-12-31$15.00B1.57%
2007-12-31$14.77B3.53%
2006-12-31$14.27B14.79%
2005-12-31$12.43B17.82%
2004-12-31$10.55B26.26%
2003-12-31$8.36B51.29%
2002-12-31$5.52B37.54%
2001-12-31$4.02B16.45%
2000-12-31$3.45B7.62%
1999-12-31$3.20B21.27%
1998-12-31$2.64B12.64%
1997-12-31$2.35B6.71%
1996-12-31$2.20B15.46%
1995-12-31$1.90B17.52%
1994-12-31$1.62B19.57%
1993-12-31$1.35B-

Amgen generated $36.75B in revenue during NA 2025, up 9.95% compared to the previous quarter, and up 144.55% compared to the same period a year ago.

Amgen Revenue by Quarter

DateRevenueChange
2025-09-30$9.56B4.25%
2025-06-30$9.17B12.49%
2025-03-31$8.15B-10.31%
2024-12-31$9.09B6.86%
2024-09-30$8.50B1.37%
2024-06-30$8.39B12.64%
2024-03-31$7.45B-9.14%
2023-12-31$8.20B18.73%
2023-09-30$6.90B-1.19%
2023-06-30$6.99B14.43%
2023-03-31$6.11B-10.73%
2022-12-31$6.84B2.81%
2022-09-30$6.65B0.88%
2022-06-30$6.59B5.71%
2022-03-31$6.24B-8.88%
2021-12-31$6.85B2.09%
2021-09-30$6.71B2.76%
2021-06-30$6.53B10.59%
2021-03-31$5.90B-11.05%
2020-12-31$6.63B3.29%
2020-09-30$6.42B3.50%
2020-06-30$6.21B0.73%
2020-03-31$6.16B-0.58%
2019-12-31$6.20B8.02%
2019-09-30$5.74B-2.28%
2019-06-30$5.87B5.65%
2019-03-31$5.56B-10.80%
2018-12-31$6.23B5.52%
2018-09-30$5.90B-2.56%
2018-06-30$6.06B9.09%
2018-03-31$5.55B-4.27%
2017-12-31$5.80B0.50%
2017-09-30$5.77B-0.64%
2017-06-30$5.81B6.33%
2017-03-31$5.46B-8.40%
2016-12-31$5.96B2.65%
2016-09-30$5.81B2.16%
2016-06-30$5.69B2.91%
2016-03-31$5.53B-0.16%
2015-12-31$5.54B-3.27%
2015-09-30$5.72B6.57%
2015-06-30$5.37B6.70%
2015-03-31$5.03B-5.59%
2014-12-31$5.33B5.96%
2014-09-30$5.03B-2.88%
2014-06-30$5.18B14.58%
2014-03-31$4.52B-9.78%
2013-12-31$5.01B5.54%
2013-09-30$4.75B1.47%
2013-06-30$4.68B10.41%
2013-03-31$4.24B-4.14%
2012-12-31$4.42B2.36%
2012-09-30$4.32B-3.53%
2012-06-30$4.48B10.60%
2012-03-31$4.05B1.89%
2011-12-31$3.97B0.74%
2011-09-30$3.94B-0.38%
2011-06-30$3.96B6.83%
2011-03-31$3.71B-3.51%
2010-12-31$3.84B0.66%
2010-09-30$3.82B0.32%
2010-06-30$3.80B5.90%
2010-03-31$3.59B-5.70%
2009-12-31$3.81B-0.08%
2009-09-30$3.81B2.67%
2009-06-30$3.71B12.24%
2009-03-31$3.31B-11.81%
2008-12-31$3.75B-3.20%
2008-09-30$3.88B2.95%
2008-06-30$3.76B4.18%
2008-03-31$3.61B-

Amgen generated $9.56B in revenue during Q3 2025, up 4.25% compared to the previous quarter, and up 113.94% compared to the same period a year ago.

Amgen Revenue Breakdown

Amgen Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 25Dec 24Dec 23Dec 22
EVENITY$2.10B$1.56B--
KRYSTEXXA$1.34B$1.19B--
Nplate$1.52B$1.46B$1.31B-
TEZSPIRE$1.48B$972.00M--
TEPEZZA$1.90B$1.85B--
Repatha$3.02B---
Prolia$4.41B$4.37B$3.63B-
Product and Service, Other$1.60B$1.40B$1.52B-
Other Products$7.26B$5.63B$5.57B-
Otezla$2.27B$2.13B$2.29B-
XGEVA$2.08B$2.23B$2.01B-
Vectibix$1.18B$1.04B--
Aranesp$1.39B$1.34B$1.42B-
BLINCYTO$1.56B$1.22B--
ENBREL$2.23B$3.32B$4.12B-
Repatha (evolocumab)-$2.22B$1.30B-
Kyprolis-$1.50B$1.25B-
Evenity--$787.00M-
Other--$1.28B-
Human Therapeutics--$26.91B-
Product---$17.30B
Neulasta---$1.13B

Amgen's latest annual revenue breakdown by segment (product or service), as of Dec 25: Other Products (20.55%), Prolia (12.49%), Repatha (8.53%), Otezla (6.41%), ENBREL (6.30%), EVENITY (5.94%), XGEVA (5.90%), TEPEZZA (5.38%), Product and Service, Other (4.54%), BLINCYTO (4.41%), Nplate (4.31%), TEZSPIRE (4.18%), Aranesp (3.93%), KRYSTEXXA (3.79%), and Vectibix (3.32%).

Quarterly Revenue by Product

Product/ServiceDec 25Sep 25Jun 25Mar 25Dec 24Sep 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Sep 20
Aranesp$333.00M$357.00M$359.00M$340.00M$656.00M$337.00M$349.00M$319.00M$323.00M-----------
Other Products$2.07B$1.85B$1.69B$1.65B$1.37B$200.00M$1.64B-------------
Otezla$625.00M$585.00M$618.00M$437.00M$1.17B$564.00M$394.00M$629.00M$567.00M-----------
Nplate$385.00M$457.00M$369.00M$313.00M$683.00M$456.00M$317.00M$386.00M$419.00M-----------
KRYSTEXXA$435.00M$320.00M$349.00M$236.00M$640.00M$310.00M$235.00M-------------
EVENITY$599.00M$541.00M$518.00M$442.00M$822.00M$399.00M$342.00M$307.00M------------
Product and Service, Other$499.00M$420.00M$408.00M$276.00M$329.00M$363.00M$355.00M$303.00M$259.00M$287.00M$415.00M$313.00M$507.00M$575.00M$386.00M$412.00M$309.00M$319.00M--
Prolia$1.05B$1.14B$1.12B$1.10B$2.33B$1.04B$999.00M$1.11B$986.00M-----------
BLINCYTO$413.00M$392.00M$384.00M$370.00M$645.00M$327.00M$244.00M-------------
TEPEZZA$457.00M$560.00M$505.00M$381.00M$939.00M$488.00M$424.00M-------------
TEZSPIRE$474.00M$377.00M$342.00M$285.00M$530.00M$269.00M$173.00M-------------
Vectibix$319.00M$284.00M$305.00M$267.00M$516.00M$282.00M$247.00M-------------
XGEVA$447.00M$539.00M$532.00M$566.00M$1.12B$541.00M$561.00M$527.00M$519.00M-----------
ENBREL$532.00M$580.00M$604.00M$510.00M$1.92B$825.00M$567.00M$1.01B$1.03B-----------
Kyprolis-$359.00M$378.00M$324.00M$749.00M$378.00M$376.00M$350.00M$349.00M-----------
Repatha (evolocumab)-$794.00M$696.00M$656.00M$1.14B$567.00M$517.00M$417.00M$406.00M-----------
Product--------$6.55B$6.55B$6.27B---------

Amgen's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: Other Products (23.98%), Prolia (12.19%), Otezla (7.23%), EVENITY (6.93%), ENBREL (6.15%), Product and Service, Other (5.77%), TEZSPIRE (5.48%), TEPEZZA (5.29%), XGEVA (5.17%), KRYSTEXXA (5.03%), BLINCYTO (4.78%), Nplate (4.45%), Aranesp (3.85%), and Vectibix (3.69%).

Amgen Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 25Dec 24Dec 23Dec 22Dec 21
UNITED STATES$26.42B$23.86B$19.81B$18.59B$1.43B
Non-US$10.33B$9.56B$8.38B$7.73B$584.00M

Amgen's latest annual revenue breakdown by geography, as of Dec 25: UNITED STATES (71.89%), and Non-US (28.11%).

Quarterly Revenue by Country

CountryDec 25Sep 25Jun 25Mar 25Dec 24Sep 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Sep 21Jun 21Mar 21Dec 20Sep 20
Non-US$3.29B$2.39B$2.45B$2.21B$5.24B$2.17B$2.15B$2.71B$1.86B$143.00M$152.00M$126.00M$132.00M$142.00M$134.00M$145.00M$133.00M$134.00M$133.00M$118.00M
UNITED STATES$7.68B$6.75B$6.32B$5.66B$12.91B$5.98B$4.97B$6.40B$4.69B$387.00M$384.00M$358.00M$363.00M$391.00M$368.00M$372.00M$355.00M$334.00M$369.00M$363.00M

Amgen's latest quarterly revenue breakdown by geography, as of Dec 25: UNITED STATES (70.03%), and Non-US (29.97%).

Amgen Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
NVONovo Nordisk$232.26B$65.35B
MRKMerck$65.01B$17.28B
PFEPfizer$62.58B$16.65B
BMYBristol-Myers Squibb$48.19B$12.22B
NVSNovartis$46.66B$11.83B
SNYSanofi$43.07B$11.12B
AMGNAmgen$36.75B$9.56B
GSKGSK$30.33B$7.36B
GILDGilead Sciences$29.44B$7.77B
DHRDanaher$24.57B$6.05B
BSXBoston Scientific$20.07B$5.07B

AMGN Revenue FAQ

What is Amgen’s yearly revenue?

Amgen's yearly revenue for 2025 was $36.75B, representing an increase of 9.95% compared to 2024. The company's yearly revenue for 2024 was $33.42B, representing an increase of 18.57% compared to 2023. AMGN's yearly revenue for 2023 was $28.19B, representing an increase of 7.09% compared to 2022.

What is Amgen’s quarterly revenue?

Amgen's quarterly revenue for Q3 2025 was $9.56B, a 4.25% increase from the previous quarter (Q2 2025), and a 12.40% increase year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $9.17B, a 12.49% increase from the previous quarter (Q1 2025), and a 9.29% increase year-over-year (Q2 2024). AMGN's quarterly revenue for Q1 2025 was $8.15B, a -10.31% decrease from the previous quarter (Q4 2024), and a 9.43% increase year-over-year (Q1 2024).

What is Amgen’s revenue growth rate?

Amgen's revenue growth rate for the last 3 years (2023-2025) was 30.37%, and for the last 5 years (2021-2025) was 41.46%.

What are Amgen’s revenue streams?

Amgen's revenue streams in c 25 are EVENITY, KRYSTEXXA, Nplate, TEZSPIRE, TEPEZZA, Repatha, Prolia, Product and Service, Other, Other Products, Otezla, XGEVA, Vectibix, Aranesp, BLINCYTO, and ENBREL. EVENITY generated $2.1B in revenue, accounting 5.94% of the company's total revenue, up 34.36% year-over-year. KRYSTEXXA generated $1.34B in revenue, accounting 3.79% of the company's total revenue, up 13.08% year-over-year. Nplate generated $1.52B in revenue, accounting 4.31% of the company's total revenue, up 4.67% year-over-year. TEZSPIRE generated $1.48B in revenue, accounting 4.18% of the company's total revenue, up 52.06% year-over-year. TEPEZZA generated $1.9B in revenue, accounting 5.38% of the company's total revenue, up 2.81% year-over-year. Repatha generated $3.02B in revenue, accounting 8.53% of the company's total revenue Prolia generated $4.41B in revenue, accounting 12.49% of the company's total revenue, up 0.91% year-over-year. Product and Service, Other generated $1.6B in revenue, accounting 4.54% of the company's total revenue, up 14.66% year-over-year. Other Products generated $7.26B in revenue, accounting 20.55% of the company's total revenue, up 29.01% year-over-year. Otezla generated $2.26B in revenue, accounting 6.41% of the company's total revenue, up 6.54% year-over-year. XGEVA generated $2.08B in revenue, accounting 5.90% of the company's total revenue, down -6.34% year-over-year. Vectibix generated $1.18B in revenue, accounting 3.32% of the company's total revenue, up 12.44% year-over-year. Aranesp generated $1.39B in revenue, accounting 3.93% of the company's total revenue, up 3.50% year-over-year. BLINCYTO generated $1.56B in revenue, accounting 4.41% of the company's total revenue, up 28.21% year-over-year. ENBREL generated $2.23B in revenue, accounting 6.30% of the company's total revenue, down -32.87% year-over-year.

What is Amgen’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of Amgen was Other Products. This segment made a revenue of $7.26B, representing 20.55% of the company's total revenue.